Proteomics

Proteomics has been widely applied to several biomedical fields in recent years. The high-throughput capability of proteomics allows simultaneous examination of numerous proteins and offers the possibility of a global analysis of proteins in cells, tissues or biofluids. The rapid progress in the field of proteomics is based primarily on the success of protein separation sciences (either gel-based or gel-free techniques) and recent advances of mass spectrometry. Unlike the genome, the proteome is dynamic and varies according to cell type and functional state of the cell. In addition, gene expression does not always correlate with protein expression as one gene can be modified to be several products or proteins that directly govern cellular function. Thus, proteome analysis is expected to provide a wealth of useful information in nutrition research on the effects of nutrients or food components on metabolic pathways. Such research allows experts to explore the regulatory mechanisms for maintaining normal homeostasis during nutritional imbalance, to better understand the pathogenic mechanisms and pathophysiology of nutritional disorders, to define molecular targets of bioactive food components and to identify biomarkers that can be used as diagnostic, predictive or prognostic factors. This paper will provide a brief overview of proteomics, a summary of current proteomic technologies and an example of proteomic application to nutrition research. Finally, the concept of systems biology, which involves integrative 'omics' (i.e., combining genomics, transcriptomics, proteomics, lipomics and metabolomics) as well as bioinformatics and modeling, will be discussed. Due to the extent of information that can be obtained from systems biology, this ideal approach holds great promise for future nutrition research.

Drug Discovery and Development in the Age of Molecular Medicine

Drug discovery might be better termed drug invention. Discoveries take place globally, and many arise from academia and research institutes. The job of the biotechnology and pharmaceutical industry is to identify those that stand the greatest chance of being turned into medicines to improve health-in other words, to invent a practical outcome on the basis of discovery. In this commentary we identify some of the areas in which molecular medicine has had the greatest impact and continues to change the invention of medicines.

Recent advances in molecular techniques for the detection of phylogenetic markers and functional genes in microbial communities

The detection and analysis of nucleic acids extracted from microbial communities are the ultimate ways to determine the diversity and functional capability of microbial communities in the environments. However, it remains a challenge to use molecular techniques for unequivocal determination and quantification of microbial species composition and functional activities. Considerable efforts have been made to enhance the capability of molecular techniques. Here an update of the recent developments in molecular techniques for environmental microbiology is provided.

Congenital myopathies

PURPOSE OF REVIEW

The aim of this review is to provide an up-to-date personal analysis of current congenital myopathy research.

RECENT FINDINGS

In the past year novel congenital myopathies have been suggested, genes have been discovered for some of the congenital myopathies for the first time (beta-tropomyosin in cap disease and perhaps skeletal muscle alpha-actin in Zebra body myopathy), further genes have been identified for congenital myopathies where other genes had already been found (cofilin in nemaline myopathy, selenoprotein N in congenital fibre type disproportion) and recessive myosin storage myopathy was associated with homozygous mutation of slow-skeletal/beta-cardiac myosin which was already known to be mutated in dominant myosin storage myopathy. There has been further clarification of the pathobiology of the congenital myopathies, including determination of the basis of epigenetic effects: silencing of the normal allele in recessive central core disease and persistence of cardiac (fetal) alpha-actin in nemaline myopathy patients with no skeletal actin.

SUMMARY

The increased understanding of the genes and pathobiology of the congenital myopathies that is developing should ultimately lead to effective treatments.

Thyroid cancer: are molecular studies making any difference?

'Translational research' encompasses all activities that apply basic scientific research findings to clinical practice. Although it has taken almost 20 years since the first scientific discoveries, the approval of new 'drugs' such as Herceptin and Avastin represents a successful example. There has also been successful translation of science into the clinic in the field of otolaryngology. In the last decade, we have seen major developments in molecular biology and genetics. Two notable achievements have been the completion of the human genome project and the parallel advances in high-throughput molecular genomic and proteomic technologies. Linked with these events has been the enormous accumulation of new data which offers the promise of important future clinical applications. This review aims to discuss these major scientific developments, to demonstrate successes in thyroid translational research, and to summarise more recent research findings in thyroid disease which provide hope for the development of future clinical tools.

Molecular genetics of arrhythmogenic right ventricular cardiomyopathy: emerging horizon?

PURPOSE OF REVIEW

Recent developments in the elucidation of genes underlying arrhythmogenic right ventricular cardiomyopathy and possible pathogenic mechanisms will be highlighted.

RECENT FINDINGS

The cardiac desmosome is a multiprotein structure involved in cell-cell interactions. Mutations in genes encoding desmosomal proteins such as PKP2, DSP, JUP, DSC2 and DSG2 underlie arrhythmogenic right ventricular cardiomyopathy, which can therefore be considered a desmosome cardiomyopathy. Mutations in the plakophilin-2 gene are most prevalent. Current pathophysiological insights suggest a final common pathway in which plakoglobin release from the desmosome, independent of the primarily affected desmosomal protein, results in desmosome impairment, intercalated disc remodeling and Wnt/beta-catenin pathway signaling defects. The recognition of left ventricular involvement associated with mutations in desmosomal protein genes and low penetrance suggests that formal criteria should not be followed too closely in selecting patients for DNA analysis, because finding a mutation may have important implications for clinical practice.

SUMMARY

Recent developments have demonstrated that arrhythmogenic right ventricular cardiomyopathy can be considered a desmosome cardiomyopathy. Left ventricular involvement is not uncommon in this type of cardiomyopathy. Such findings are important for diagnostics and family screening and form a starting-point for the elucidation of other (non)-genetic factors influencing disease progression and outcome.

Common neurodegenerative diseases: dissection by genome-wide association

Genome-wide association studies have already yielded great results. The success of this method in several common diseases leaves little doubt that it will aid in deciphering the genetic bases of the most common and devastating neurodegenerative disorders.

Molecular Imaging: Integration of Molecular Imaging into the Musculoskeletal Imaging Practice

Chronic musculoskeletal diseases such as arthritis, malignancy, and chronic injury and/or inflammation, all of which may produce chronic musculoskeletal pain, often pose challenges for current clinical imaging methods. The ability to distinguish an acute flare from chronic changes in rheumatoid arthritis, to survey early articular cartilage breakdown, to distinguish sarcomatous recurrence from posttherapeutic inflammation, and to directly identify generators of chronic pain are a few examples of current diagnostic limitations. There is hope that a growing field known as molecular imaging will provide solutions to these diagnostic puzzles. These techniques aim to depict, noninvasively, specific abnormal cellular, molecular, and physiologic events associated with these and other diseases. For example, the presence and mobilization of specific cell populations can be monitored with molecular imaging. Cellular metabolism, stress, and apoptosis can also be followed. Furthermore, disease-specific molecules can be targeted, and particular gene-related events can be assayed in living subjects. Relatively recent molecular and cellular imaging protocols confirm important advances in imaging technology, engineering, chemistry, molecular biology, and genetics that have coalesced into a multidisciplinary and multimodality effort. Molecular probes are currently being developed not only for radionuclide-based techniques but also for magnetic resonance (MR) imaging, MR spectroscopy, ultrasonography, and the emerging field of optical imaging. Furthermore, molecular imaging is facilitating the development of molecular therapies and gene therapy, because molecular imaging makes it possible to noninvasively track and monitor targeted molecular therapies. Implementation of molecular imaging procedures will be essential to a clinical imaging practice. With this in mind, the goal of the following discussion is to promote a better understanding of how such procedures may help address specific musculoskeletal issues, both now and in the years ahead.

Animal models of spinal muscular atrophy

Spinal muscular atrophy, a common autosomal recessive motor neuron disorder, is caused by the loss of the survival motor neuron gene (SMN1). SMN2, a nearly identical copy gene, is present in all spinal muscular atrophy patients but differs by a critical nucleotide that alters exon 7 splicing efficiency. This results in low survival motor neuron protein levels, which are not enough to sustain motor neurons. SMN disruption has been undertaken in different organisms (yeast, nematode, fly, zebrafish, and mouse) in an attempt to model this disease and gain fundamental knowledge about the survival motor neuron protein. This review compares the various animal models generated to date and summarizes a research picture that reveals a pleiotropic role for survival motor neuron protein; this summary also points to unique requirements for survival motor neuron protein in motor neurons. It is hoped that these observations will aid in pointing towards complementary paths for therapeutic discovery research.

Recently Described and Emphasized Entities of Renal Neoplasms

Context.—Recent advances of molecular biology and cytogenetics of renal cancer have resulted in the new classification of renal neoplasms and a number of subtypes are identified and emphasized. In addition, rare nonepithelial renal neoplasms are identified and characterized. Familiarity with these entities will help make the most accurate diagnosis and guide the treatment and follow-up of patients with renal neoplasm.

Objective.—To review the clinicopathologic entities of renal neoplasms that are recently defined or emphasized. Their clinical, gross, microscopic, and immunohistochemical features, as well as specific cytogenetic or molecular abnormalities, are discussed. Important differential diagnoses of each entity are also briefly discussed.

Data Sources.—Extensive review of published literature and our experience.

Conclusions.—A number of new entities of renal neoplasms or genetically defined renal cell carcinomas have been identified or emphasized because of their unique genetic or molecular changes. Recognition of these entities becomes important as some of them have different biologic behavior and treatment strategies may be different.

Spinal muscular atrophy: classification, diagnosis, management, pathogenesis, and future research directions

Spinal muscular atrophy is an autosomal recessive neurodegenerative disorder that affects the motor neurons responsible for movement of the proximal muscles of the trunk and body. To date, the disease can be classified into 3 main categories based on severity and age of onset. During the October 18th symposium held in Pittsburgh, Pennsylvania, researchers met to (1) describe current diagnostic strategies, (2) discuss recent thoughts on pathogenesis, (3) review current therapies and clinical trials, and (4) define future research directions. In her opening remarks, Dr Story Landis, director of the National Institute of Neurological Disorders and Stroke, emphasized the degree to which the Neurobiology of Disease in Children conference series has broadened awareness of the many rare diseases affecting children, not only through the advancement of research but also by educating practitioners about diagnostic strategies. Dr Landis also discussed the role this conference may play in fostering research that seeks to develop a single mechanism of therapy for spinal muscular atrophy. She also discussed the current funding situation at the National Institutes of Health and addressed the crucial function of volunteer research organizations that sponsor research in further improving management of this condition. This article summarizes the presentations and includes the verbatim edited transcript of question-and-answer sessions.

[Paradigm shift in surgical pathology of cancer: molecular diagnostics, prognosticators and predictive pathology]

Classical methodology of surgical pathology extended first with ultrastructural methods, then with immunohistochemistry and more recently with molecular/ genomic techniques. These changes added new dimensions to the classical tissue-and cellular levels of diagnostics: the molecular level. This change is the primary motor of the development of the diagnostic as well as the prognostic and predictive pathology. It is now possible to identify an etiological factor (HPV) or reclassify an entire entity (soft tissue tumors). Prognosis of cancer relies more and more on molecular/genetic parameters such as microsatellite instability, gene amplifications etc. Targeted therapy of cancer develops parallel with the molecular predictive pathology such as the anti-HER2 or anti-EGFR therapies. In conclusion, it is fair to say that molecular pathology contributes significantly to the development of clinical oncology.

The evaluation of genetic tests

Scientific advances in genetics and molecular biology have been very successful in advancing our knowledge of biological mechanisms in health and disease, and in catalysing a variety of technological innovations. The number of genetic tests available has consequently increased exponentially over the last few years. Their development has not been accompanied by processes and systems to evaluate these tests in a proper and formal manner to establish their clinical validity and utility. A framework for the evaluation of genetic tests has been developed. This paper reviews the current practice of genetic test evaluation, highlighting the limitations and future challenges in this area of public health.

Genetik der Angsterkrankungen

The authors give an overview of the present state of knowledge on the genetics of anxiety disorders. According to ICD-10 or DSM III/IV classification, anxiety disorders comprise panic disorder, generalized anxiety, phobias, and post-traumatic stress disorder. In the context of the conceptual change from psychodynamic anxiety neuroses to complex, multifactorial anxiety disorders, a summary of biological hypotheses of the pathogenesis of anxiety derived from pharmacotherapy, challenge tests, and animal model disorders is provided. The relevant findings from clinical genetic studies (twin and family) and molecular genetic studies (linkage and association) are presented in detail. The most data now available are on panic disorder, though with regard to molecular genetics these are still preliminary. In addition, genetic findings on anxiety as a personality dimension are reviewed, taking into account the present phenotype discussion (category vs dimension). Finally, ethical and therapeutic implications of genetic research on complex, polygenic disorders are discussed.

Chemical genetics: elucidating biological systems with small-molecule compounds

Chemical genetics employs diverse small-molecule compounds to elucidate biological processes in a manner analogous to the mutagenesis strategies at the core of classical genetics. Screening small-molecule libraries for compounds that induce a phenotype of interest represents the forward chemical genetic approach, whereas the reverse approach involves small molecules targeting a single protein. Here, we review key differences between the goals for small-molecule screening in industry versus academia, recent developments in high-throughput screening, and publicly available resources of compound collections, screening facilities, and databases. A particularly exciting outcome of a chemical genetic screen is the discovery of a previously unknown role for a protein in a pathway together with compounds that affect the function of that protein. In illustrative cases, such discoveries have led to progress toward therapeutic development and more commonly have increased the size of the small molecule "toolbox" available to the research community for the study of biological processes.

Identification of Novel Pigmentation Modulators by Chemical Genetic Screening

There is a continual need for compounds that effectively modulate melanin synthesis. To identify novel pigmentation modulators and their cellular targets, chemical genetic screenings were performed with triazine-based combinatorial libraries that include various linkers as intrinsic components of the small molecules in the library. The linker provides a ready means of attachment to beads, eliminating several common time-consuming downstream steps in the isolation of cellular targets for the small molecules of interest. Twelve compounds were identified as novel pigmentation modulators from various screenings performed in normal and albino murine melanocytes and zebrafish. Target identification by affinity chromatography revealed unexpected roles for prohibitin and mitochondrial F1F0-adenotriphosphatase in the regulation of mammalian pigmentation. The identification of prohibitin, a "scaffold protein", as a propigmentation effector represents a novel mechanism by which propigmentary signals are transduced. Results from our screenings provide potential active agents and targets for the medical and aesthetic treatment of disorders of pigmentation.

Molecular genetics of meningiomas: from basic research to potential clinical applications

To review our current understanding of the molecular pathogenesis of meningiomas, to suggest topics for future investigations, and to present perspectives for clinical application. Significant progress has been made in recent years in delineating the molecular mechanisms involved in meningioma formation, growth, and malignant progression. However, many questions remain unanswered. Mutations in the NF2 gene probably account for the formation of more than half of all meningiomas. On the other hand, the molecular events underlying the initiation of meningiomas without NF2 mutations have yet to be identified. Investigating hereditary conditions associated with an increased meningioma incidence and the mechanisms underlying the development of radiation-induced meningiomas could potentially yield relevant insights. Meningioma growth is sustained by the dysregulated expression of steroid hormones, growth factors, their receptors, and activation of signal transduction cascades. The underlying genetic causes are unknown. Malignant progression of meningiomas probably involves the inactivation of tumor suppressor genes on chromosomes 1p, 9p, 10q, and 14q. However, with the possible exception of INK4A/INK4B, the actual targets of these chromosomal losses have remained largely elusive. Cell cycle dysregulation and telomerase activation have been recognized as important steps in meningioma progression. Telomere dynamics, cell cycle control, and the mechanisms responsible for deoxyribonucleic acid damage control are tightly interwoven. Investigating genes involved in the maintenance of genomic integrity might significantly deepen the understanding of meningioma progression. An area that has received relatively little attention thus far is the genetic background of meningioma spread and invasion. Possible clinical applications of the molecular data available may include a meningioma grading system based on genetic alterations, as well as therapeutic strategies for refractory meningiomas aimed at interfering with signal transduction pathways.

Biologistes sans frontières

Junior researchers are encouraged to gain experience abroad, and for senior scientists, sabbaticals remain popular. France has taken the next step in fostering international exchange, by supporting long-term collaborations with foreign laboratories and by creating research units abroad.

Metastasis: recent discoveries and novel treatment strategies

Most cancer deaths are due to the development of metastases, hence the most important improvements in morbidity and mortality will result from prevention (or elimination) of such disseminated disease. Some would argue that treatments directed against metastasis are too late because cells have already escaped from the primary tumour. Such an assertion runs contrary to the significant but (for many common adult cancers) fairly modest improvements in survival following the use of adjuvant radiation and chemotherapy designed to eliminate disseminated cells after surgical removal of the primary tumour. Nonetheless, the debate raises important issues concerning the accurate early identification of clonogenic, metastatic cells, the discovery of novel, tractable targets for therapy, and the monitoring of minimal residual disease. We focus on recent findings regarding intrinsic and extrinsic molecular mechanisms controlling metastasis that determine how, when, and where cancers metastasise, and their implications for patient management in the 21st century.

Molecular imaging: the vision and opportunity for radiology in the future

Molecular imaging is being hailed as the next great advance for imaging. This introductory article in the molecular imaging series to be published over the next several months in Radiology sets the stage for the subsequent set of articles by providing relevant definitions and background information and traces the evolution of molecular imaging to its current state of research and clinical practice. It discusses in detail the evolution of molecular imaging and the role that the National Cancer Institute and the National Institutes of Health have had in the funding and development of many of the important molecular imaging research programs that are in existence today. The article also provides basic information about the complex biology of the cell and details of the pathogenesis of cancer and how molecular imaging will be critical for earlier detection and management of cancer in the future. The article lays the foundation for the subsequent articles in the series and describes how and why molecular imaging will be critical and integral for clinical care of patients in the future. The introductory article also discusses the relevance of molecular imaging to clinical radiology practice and why it is critical for the practicing radiologist to understand these evolving techniques, as they will be the future of imaging.

Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data

BACKGROUND

The cause of sporadic ALS is currently unknown. Despite evidence for a role for genetics, no common genetic variants have been unequivocally linked to sporadic ALS. We sought to identify genetic variants associated with an increased or decreased risk for developing ALS in a cohort of American sporadic cases.

METHODS

We undertook a genome-wide association study using publicly available samples from 276 patients with sporadic ALS and 271 neurologically normal controls. 555 352 unique SNPs were assayed in each sample using the Illumina Infinium II HumanHap550 SNP chip.

FINDINGS

More than 300 million genotypes were produced in 547 participants. These raw genotype data are freely available on the internet and represent the first publicly accessible SNP data for ALS cases. 34 SNPs with a p value less than 0.0001 (two degrees of freedom) were found, although none of these reached significance after Bonferroni correction.

INTERPRETATION

We generated publicly available genotype data for sporadic ALS patients and controls. No single locus was definitively associated with increased risk of developing disease, although potentially associated candidate SNPs were identified.

Mitochondrial DNA and its mutations: novel fields in a new era

Az utóbbi két évtizedet tartják a klinikai mitokondriális DNS-kutatás aranykorának. Folyamatosan bővül a patológiás variánsok száma, amelyek betegséggel társulnak, illetve bővül az ismeretanyag azokról az entitásokról, melyek hátterében a mitokondriális DNS kóros elváltozásai állnak. A cirkuláris mitokondriális DNS öröklődése eltér a Mendel-féle szabályoktól, anyai öröklésmenetet mutat; számos vonatkozásban eltérő sajátosságokkal rendelkezik a nukleáris DNS-hez viszonyítva. A molekuláris biológiai módszerek terjedésével egyre több kórkép ismerhető fel, noha a diagnosztika manapság is komoly kihívást jelent. Napjainkban a mitokondriális medicina számos orvosi szubspecialitáshoz kapcsolódóan jelentős előrelépéseket mutatott; így körvonalazódott a mitokondriális gasztroenterológia, endokrinológia, otológia, oftalmológia, nefrológia, hematológia, onkológia, reproduktív medicina és pszichiátria, mintegy az adott szubspecialitás mitokondriális DNS-sel kapcsolatos, többé-kevésbé részleges önállósodással megjelenő territóriuma. A jelen összefoglaló közlemény a mitokondriális medicina rövid, általános összefoglalása mellett e fejezetekre próbál rátekintést nyújtani.

The returning tide: how China, the world's most populous country, is building a competitive research base

When China turned its back on the Cultural Revolution, it aimed to build a thriving capitalist sector. It got one. Now, it wants a world-class research enterprise. How far has it progressed in the biosciences, how did it get there, and how far does it have to go?

Single molecule biology: coming of age

Cellular heterogeneity and stochastic fluctuation play key roles in biological processes. Single molecule approaches have the key advantage of avoiding ensemble averaging, allowing the observation of transient intermediates and heterogeneity (both static and dynamic). Thus they have revolutionised the way many biological questions are addressed. The challenge ahead is to develop integrated approaches such as the combination of single molecule imaging with single molecule manipulation to probe the dynamics of gene regulatory and cell signalling networks in living cells.

Survey of treatment recommendations for anaplastic oligodendroglioma

Anaplastic oligodendroglioma is a malignant brain tumor uniquely sensitive to treatment with both chemotherapy and radiotherapy. There are few prospective clinical trials for newly diagnosed patients and multiple approaches to the treatment of these patients. This study explored the recommended treatment offered by experts in neuro-oncology. A Web-based survey was developed and distributed to 800 members of the Society of Neuro-Oncology (SNO) who had an e-mail address listed with SNO. Questions addressed use of molecular genetic information and treatment recommendations. A total of 99 clinical SNO members (20%) responded. The majority reported practicing at an academic center in the United States. Two-thirds of respondents see more than five patients with newly diagnosed anaplastic oligodendroglioma annually. Molecular genetic testing was requested for more than 75% of patients, and the results significantly influenced treatment recommendations (p = 0.000003). Regardless of molecular genetic status, the most commonly recommended treatment was the use of concurrent temozolomide and radiotherapy followed by adjuvant temozolomide (18%-34%). The current survey demonstrates that although neuro-oncologists have embraced the use of molecular genetic studies in newly diagnosed anaplastic oligodendroglioma, treatment recommendations vary widely and are often independent of the molecular data.

Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: Where do we stand?

Tumors have usually been classified by their morphologic appearances. Unfortunately, these current classification schemes have serious drawbacks. They are not able to stratify similar histopathological appearances that will follow significantly different clinical courses or respond differently to chemotherapy. The information that a specific molecular profile correlates with important clinical endpoints should permit physicians to take treatment decisions based on the molecular characteristics of each tumor. Lessons from the metastatic setting have been translated to the adjuvant setting, and several strategies have been evaluated in clinical trials. The expression of estrogen receptors (ER) in breast cancer enables physicians to make treatment decisions related to the use of hormonal manipulations. In this context, the challenge is to define a suitable subgroup of patients who will benefit from the addition of chemotherapy. Otherwise, the lack of ER expression predicts no benefit from hormonotherapy. In this setting chemotherapy plays a central role. The selection of the most appropriate regimen based on HER-2 status remains an uncertain strategy. However, the expression of the oncoprotein HER-2 has been linked to the probability of response to the target-designed monoclonal antibody trastuzumab. The role of trastuzumab in the adjuvant setting is supported by the early results of three large clinical trials presented at the American Society Clinical Oncology meeting in 2005. These trials have shown a striking impact of trastuzumab on the main endpoints such as disease-free survival and overall survival. In this context, the integration of trastuzumab with taxane and anthracycline-based-chemotherapy seems to be the appropriate choice. This review will combine data from breast cancer biology with clinical evidence coming from large phase III trials in the attempt to propose a molecular targeted approach to the adjuvant treatment strategy of early breast cancer patients.

Plastid biotechnology: prospects for herbicide and insect resistance, metabolic engineering and molecular farming

Transgene expression from the chloroplast (plastid) genome offers several attractions to plant biotechnologists, including high-level accumulation of foreign proteins, transgene stacking in operons and a lack of epigenetic interference with the stability of transgene expression. In addition, the technology provides an environmentally benign method of plant genetic engineering, because plastids and their genetic information are maternally inherited in most crops and thus are largely excluded from pollen transmission. During the past few years, researchers in both the public and private sectors have begun to explore possible areas of application of plastid transformation in plant biotechnology as a viable alternative to conventional nuclear transgenic technologies. Recent proof-of-concept studies highlight the potential of plastid genome engineering for the expression of resistance traits, the production of biopharmaceuticals and metabolic pathway engineering in plants.

Genomics and toxic torts: dismantling the risk-injury divide

Emerging genetic and molecular technologies are revolutionizing our understanding of the relationship between genes and the environment. This Article develops an innovative framework for understanding the implications of the genomic revolution for the law of toxic torts. Professor Grodsky demonstrates how new technologies are poised to challenge longstanding distinctions between legally inconsequential "risk" and remediable "injury," and how the U.S. legal system will need to adapt to this emerging reality. If the law remains wedded to conventional notions of injury, it will ignore the fruits of a scientific revolution and thus may forego new remedial opportunities as yet unimagined. This is particularly significant given that twenty-first century medicine strives to "go beyond the limitations of biology" and detect, prevent, and treat disease at the molecular level. The transformative and rapidly evolving technologies of the genomic era will present herculean challenges for the legal system. But opportunities to fashion new remedies and create new efficiencies must not be overlooked in the process. Professor Grodsky recommends legal approaches to balance the goals of deterrence and legal restraint in an age of accelerating scientific change.

Genetic screening for signal transduction in the era of network biology

In contrast to animal-based mutant phenotype assays, recent biochemical and quantitative genetic studies have identified hundreds of potential regulators of known signaling pathways. We discuss the discrepancy between previous models and new data, put forward a different signaling conceptual framework incorporating time-dependent quantitative contributions, and suggest how this new framework can impact our study of human disease.

Advanced molecular tools for the identification of lactic acid bacteria

Recent years have seen an explosion in the development and application of molecular tools for identifying microbes and analyzing their activity. These tools are increasingly applied to strains of lactic acid bacteria (LAB), including those used in fermentation and as well as those marketed as probiotics, for identification and analysis of their activity. Many of these tools are based on 16S ribosomal DNA sequences and exploit either hybridization or PCR techniques. Furthermore, complete or partial genomes of various LAB and bifidobacteria have been determined and offer omics-based approaches to analyze the activity of the bacteria provided that the mechanisms of their action are known. Finally, fluorescent probes coupled to flow cytometry are used to monitor the physiological capacity of bacterial cells in situ. All these approaches can be used for the screening and selection of LAB, assessing their role in fermentation and flavor development in fermented products. Additional aspects of probiotic LAB include their viability and vitality during processing and analysis of their presence, persistence, and performance in the gastrointestinal tract. An overview of these approaches is provided, and specific examples of their application to lactic cultures are presented. Because of their abundant use in tracing and tracking of LAB, a complete listing of 16S ribosomal RNA probes for lactobacilli and bifidobacteria is provided.

How technology is reshaping the practice of nongynecologic cytology: frontiers of cytology symposium

To pay tribute to the Founders of Acta Cytologica, this Golden Anniversary symposium on nongynecologic cytology revives the written symposium style of the 1950s. Participants from countries throughout the world were asked how new technologies are currently applied in their laboratories and whether future advances and challenges can be predicted. The specific questions and the participants' answers follow.

Exploring mechanochemical processes in the cell with optical tweezers

Force and torque, stress and strain or work are examples of mechanical and elastic actions which are intimately linked to chemical reactions in the cell. Optical tweezers are a light-based method which allows the real-time manipulation of single molecules and cells to measure their interactions. We describe the technique, briefly reviewing the operating principles and the potential capabilities to the study of biological processes. Additional emphasis is given to the importance of fluctuations in biology and how single-molecule techniques allow access to them. We illustrate the applications by addressing experimental configurations and recent progresses in molecular and cell biology.

It is all about resolution. Meeting report based upon presentations at the 10th International Global BioMillennium 2006 symposium on molecular cell biology (Tbilisi, Georgia)

The 2006 Global BioMillennium Conference took place in Tbilisi, Georgia, on 13-17 July 2006. The Conference was focused on key aspects of gene expression processes. Characteristic of state-of-the-art research in the life sciences, the invited lectures spanned approaches in cell biology, gene expression, and protein function. A particular aspect that is special to the BioMillenium series of conferences (this has been the 10th in this series) is the emphasis on new and emerging technologies; the various experts in the subfields that were covered presented what, in their view, should be critical to enabling future progress.